PERP and familial pancreatic carcinoma: Overall, we (a) highlight the utility of age-appropriate cancer models to identify novel cachexia-associated pathways/targets, (b) identify 3-MA as dual inhibitor of cancer-associated muscle atrophy and pancreatic tumor progression, and (c) implicate Perp as a potentially novel 3-MA target and pancreatic cancer oncogene.